“A Preview of Tomorrow: Invest in the Top 10 NASDAQ Stem Cell Stocks for 2023
As the field of stem cell research continues to grow and gain renewed attention in the world of medicine, so too does the investment opportunities associated with biotechnology companies working in the area. In 2021 alone, the Nasdaq Composite Index has seen a 27% increase in value and is projected to continue to provide sound investment opportunities over the next 5 years. According to a report from Grandview Research, the global market for stem cell therapies alone is expected to reach $124 billion by 2023. Investing in stem cell stocks can be a great way to get involved in an emerging market and the benefits it may provide in the near future. As research and technological advancements in stem cells continue, there is potential for remarkable breakthroughs to occur. While many older investors may be more comfortable with the traditional stocks of big companies, younger investors may be more comfortable with investing smaller amounts of money in individual biotechnology companies. With this in mind, these are the 10 biggest Nasdaq companies involved in stem cell research and development to watch in 2023: 1.uniQure N.V.-uniQure is a pioneering biotechnology firm focusing on drug development using advanced gene therapy. 2.Verastem Inc.–Verastem is a clinical stage biopharmaceutical company focused on discovering and developing drug treatments for cancer. 3.BioMarin Pharmaceutical Inc.–BioMarin is a biotechnology company focusing on treatments from rare diseases using recombinant gene-based therapies. 4.Cellular Dynamics International, Inc.–Cellular Dynamics is a leader in manufacturing human induced pluripotent stem (iPS) cells from biological samples. 5.Asterias Biotherapeutics, Inc.–Asterias is a biotechnology company focused on developing treatments for neurological conditions such as spinal cord injuries and stroke. 6.Cytori Therapeutics, Inc.–Cytori is a clinical stage biotechnology company focusing on autologous cell therapy for vascular diseases and disorders. 7.ReNeuron Group- ReNeuron is a development stage biotechnology company focusing on developing stem-cell based treatments for a range of diseases and disorders. 8.Capricor Therapeutics, Inc.–Capricor is a biotechnology company developing therapies for cardiac repair using adult-derived stem cells. 9.Bluebird bio, Inc.–Bluebird is a leading gene-editing biotechnology company focused on developing treatments for genetic diseases. 10.Abeona Therapeutics Inc.–Abeona is a clinical stage biotechnology company focused on discovering, developing and commercializing novel therapies for rare and orphan diseases. Stem cell stocks have become increasingly popular due to the promise they provide in terms of future treatments, and their available growth potential. With advancements and technological developments continuing to be made in the area, the future of stem cell research and development looks brighter than ever. By investing in these 10 biggest Nasdaq companies, you may be able to gain exposure to some of the most promising new treatments that will be available in 2023.